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ABSTRACT
Clinical outcomemeasures are well-established quantitative assess-
ments of medical treatment that are crucial for understanding the
effectiveness of prescribed drugs. However, recent studies suggest
that timely and long-term clinical outcome measures are not usu-
ally found in the patient records. The study attributes the lack of
quantitative follow-up to the reluctance of the clinicians treating
the patients, whose active schedules incline them to use (insuffi-
cient) brief descriptions of the cases, greatly reducing the quality of
care. To ease the clinicians burden and improve the process of pa-
tient follow-up while simultaneously dealing with the complexity
of our domain, we designed and deployed a multi-agent platform
to automate the process of collecting patient-provided clinical out-
come measures without clinicians intervention. The system also
acts as a mediator between patients and scientists, by seeking pa-
tient consent to incorporate anonymised versions of the collected
data into scientific studies to which the patients are found eligible.
This paper presents the design, prototype and deployment results of
our system, highlighting foreseen clinical merits and documenting
challenges faced throughout our experience.
Categories and Subject Descriptors
1.2.11 [Distributed Artificial Intelligence]: Multi-agent systems
General Terms
Design, Management, Reliability, Security, Standardization
Keywords
healthcare; multi-agent; automation; electronic health records
1. INTRODUCTION
The path traveled by a drug from laboratories to pharmacy shelves
is a multi-phase process unique to every drug. The pre-release
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stage usually includes Randomised control trials (RCTs), studies
whereby a random sample of patients undergoes treatment for a
specific period of time [9]. RCTs evaluate the drug’s capacity to
induce beneficial effects on the patients during the study, i.e. the
drug’s efficacy. However, in order to establish the degree to which
the same drug improves patients in the uncontrolled turbulence of
everyday practice, naturalistic treatment trials (NTTs) are used [9].
NTTs evaluate the drug’s effectiveness, its ability to induce long-
term results in a large and heterogeneous patient population. They
record patients’ progress via well-established measures of medical
care, known as clinical outcome measures, during routine clinical
practice. Ideally, clinicians are responsible for inputting the out-
come measures into the patient’s records. However, recent studies
have shown that clinicians choose to rely on their impressions in
assessing symptoms and (potentially life-threatening) side effects
and view outcome measures as a clinically-irrelevant bureaucracy
[18]. For example, a recent study evaluating the effectiveness of
treatment received by children with Attention Deficit Hyperactivity
Disorder (ADHD) in the largest mental health institute in Europe
found that only 1% of the patients have long-term follow-up mea-
sures recorded, and attributes the small percentage to the clinicians’
reluctance to record the rather lengthy outcome measures into their
databases; quite concerning results [5].
As a result, NTTs take the costly and resource-consuming form
of studies whereby designated personnel visit the patients on pre-
defined occasions to record their progress. Because patient records
are strictly confidential, these studies are also burdened with time
delays for obtaining the appropriate consent and approvals.
Having the above in mind, we began an effort to build a sys-
tem to tackle the root of the problem: the lack of timely-recorded
outcome measures data in the patients’ records. The aim is to en-
able patients to take control of the process of feedback provision
to their electronic health records, and making the data usable for
clinical evaluation purposes as well as scientific inquiry by autho-
rised researchers. In collaboration with healthcare professionals
through an extensive requirements elicitation process, we soon dis-
covered that such system will not only be complex, but also in-
volves distributed entities and is burdened by the following issues
(1) patient records are confidential, with strict rules prohibiting ac-
cess to anyone not directly involved in the treatment (2) patients
tend to visit several healthcare institutions during the course of their
treatment, distributing their records across different organisations,
each with its own set of rules, regulations and internal protocols
(3) the structure, languages and terminologies used to build elec-
tronic health records systems largely vary across hospitals, and (4)
different stakeholders with different privileges have real interest in
the feedback data, including clinicians, patients and authorised re-
search scientists. The above requirements naturally led to an agent-
based infrastructure, as we believe they fit the strengths and capa-
bilities of agent-based systems. The result is APPROaCh (Agent
Platform for automating patient PROvided Clinical outcome feed-
back). Our work relies on the idea of replacing clinicians, who are
naturally reluctant to record clinical outcome measures as part of
their routine work, by software agents. The multi-agent computing
infrastructure supports patient-provided clinical outcome measures
collection whereby the patients, guided by software agents, are ca-
pable of feeding their clinical outcomes directly back to the elec-
tronic health records of their respective organisations. We imple-
mented a system which (1) provides a cross-organisational ontol-
ogy to tackle the heterogeneity of the data found in patient records
(2) provides an online tool designed to be used by patients for the
provision of treatment outcome measures regardless of where they
are being treated and whether they visit one or several healthcare
institutions (3) automates an anonymisation pipeline designed to
create research-friendly views of the patient records in real-time,
eliminating the privacy issues associated with NTTs (4) enables
scientists in different research institutions to design and conduct
targeted studies using the anonymised version of the patient records
(5) reduces cost by automating the process of obtaining patient con-
sent in real-time, following-up and obtaining feedback from the
patients at intervals predetermined by clinicians or research scien-
tists and (6) engages with patients on timely bases to take feed-
back and provide detailed and well-studied guidance reports. This
improves the patients’ understanding of their case, facilitates self-
care and increases patient involvement with feedback provision. In
addition to improving data collection for research and quality con-
trol, APPROaCh is designed to increase patient awareness and ease
the financial and resource burden of healthcare research. We de-
signed APPROaCh using theO-MaSE methodology [6] and have
recently deployed the majority of our design in the South London
and Maudsley National Health Services Foundation Trust (SLaM)1
in London, United Kingdom.
There have been efforts to use multi-agent systems to remedy
some of the issues within NTTs and for post-marketing drug evalu-
ation in general. SARMA [21] and ePCRN-IDEA [16] build multi-
agent systems to automate the process of obtaining patient consent
for clinical trial recruitment to eliminate the privacy and distribu-
tion issue. Those systems focus on increasing the number of pa-
tients willing to participate in NTTs using automation of consent
in collaboration with clinicians and do not examine the automa-
tion of the actual trial. [14, 11] complement the clinicians’ work
by building systems to detect unknown adverse drug reactions by
examining the records of patients prescribed these drugs.
The paper is structured as follows. After some background in
Section 2, Section 3 shows the design of APPROaCh. We discuss
implementation details and deployed prototype in Section 4 and
conclude with a discussion in Section 5.
2. BACKGROUND
2.1 Clinical Outcome Measures
A notion central to our work is that of a clinical outcome mea-
sure, a well-defined numerical quantity for evaluating the quality
of medical care. Clinical outcome measures numerically establish
1www.slam.nhs.uk
the standard against which the end result of a treatment is assessed.
An extensive area of medical research is centred around the careful
design of clinical outcome measures to test the efficacy and effec-
tiveness of medical treatment for different disorders [22].
A special class of outcome measures are patient-reported out-
come measures (PROMs), which take the form of a questionnaire
to which the responses are collected from the patient. PROM ques-
tions can range from physical measurements (e.g. blood pressure)
to more exploratory questions (e.g. do you find it difficult to make
friends?). PROMs are established as useful tools for improving the
quality of care given to patients [10].
Nevertheless, PROMs are not currently enforced as part of rou-
tine clinical practice. As mentioned in the introduction, they are
seen as time-consuming and rarely acknowledge by clinicians. A
study conducted in UCLA shows that long-term outcome measures
are scarce in electronic health records, with availability ranging
from 1-10% [23]. The study concludes that consolidating outcome
measures recording with routine clinical practice is currently one
of the bottlenecks of practice-based medical research.
2.2 Agents, Healthcare and Research
Healthcare systems present several requirements which make them
attractive multi-agent environments. Healthcare systems are by
definition distributed, spanning different hospital units and con-
necting with other systems (e.g. other hospitals or general prac-
titioner clinics). They embody decision making achieved through
the coordinated efforts of a set of autonomous entities, i.e. the dif-
ferent professionals providing care (clinicians, nurses, etc..). In
addition, they are used to solve complex problems requiring the
satisfaction of different and possibly conflicting constraints, e.g.
organ transplant management [3], or problems which naturally de-
compose into (possibly interdependent) subproblems, e.g. decision
support systems [7, 12, 19]. Finally, healthcare systems require
the collection and management of heterogeneous data ranging from
clinical notes to medical information on the web to medical ontolo-
gies [17]. As a result, multi-agent systems have found many medi-
cal application ranging from resource allocation [2] to remote care
[1, 15] (see [13] for a recent review).
The requirements presented by incorporating clinical outcome
measures collection into routine care, and possibly using them for
auditing and research purposes, are not different from the above. To
begin with, several geographically-distributed stakeholders require
access to the data. These include scientists (located at a research
institution), clinicians (in one of possibly many hospitals) and pa-
tients (at home, work, hospital, etc..). These stakeholders will have
different privileges, e.g. scientists can only view records related to
studies they are involved in and only after the data has been made
anonymous, protecting the identity of participating patients. This
calls for multiple views of the data made available in real time and
enforces many privacy constraints on the distributed platform. Our
problem also involves heterogeneous data as studies centred around
specific outcome measures involve patients receiving care at differ-
ent institutions, creating a need for a representation unifying the
different electronic patient records used at the participating organ-
isations. In a nutshell, our domain presents a suitable example for
implementing a multi-agent framework.
2.3 The O-MaSE Methodology
We used the Organization-based Multiagent Systems Engineer-
ing (O-MaSE) methodology to design our agents [6]. The method-
ology guides the process of agent system development via seven
steps spanning the analysis and design phases, each producing a
model whose output feeds as input for the next. The analysis phase
includes: (1) goal hierarchy model, capturing the goals of the sys-
tem as a hierarchical structure (2) dynamic goal model, which ex-
pands the goal hierarchy by expressing dependencies and prece-
dence relations between the goals in the hierarchy (3) organisation
model (4) role model, which defines roles: the different behaviours
achieving the design goals and their interactions. The design phase
includes (5) agent class diagrams, assigning roles to agents (6) pro-
tocol models, defining agent interactions and (7) plan diagrams,
defining plans that agents can follow to satisfy organisation goals.
3. OUR SYSTEM
Here we present the design of our system, which is naturally
made up of a number of agents located in different organisations,
interacting to achieve two distinct aims: 1) to incorporate patient
feedback through PROMs into routine clinical work and 2) to en-
able scientists located at research institutions and wishing to per-
form targeted naturalistic treatment trial studies to find eligible sub-
jects through our feedback system. We achieve the first aim by
placing software agents in the primary care units of registered hos-
pitals for the task of obtaining regular and timely patient feedback.
These agents interact with the patients through e-mails and a web
interface, providing progress reports, detailed analyses and positive
messages to encourage feedback, and subsequently input their feed-
back into their clinical records. Moreover, we achieve the second
aim by enabling clinicians to identify eligible patients in real time
and discuss the study, asking for consent to include the patients’
anonymous feedback in the study. Throughout our discussions, we
highlight aspects of our system which enable it to deal with the data
diversity, security and distribution issues presented by the domain.
3.1 Object Modelling
To tackle the diversity of terminologies and languages used in
managing electronic patient records, we created an ontology-driven
model to serve as a common language understood by all the agents
created by the system regardless of their location or host organ-
isation. The model is the result of the joint effort of clinicians,
researchers and developers. A detailed specification of our ontol-
ogy is beyond the scope of this paper. However, we summarise the
most essential objects in APPROaCh.
1. PROM Model: defines the specifications of a single PROM
object and comprises of the following submodels:
(a) PROM description model: a free-text description of the
PROM.
(b) PROM eligibility model: a set-theoretic model comprising
of a number of queryable attribute sets, each defining the domain
describing one aspect of the patient’s eligibility to the PROM.
The sets in the model include the disorders set, the medications
set, the age set and the exclusion set, which comprises of ele-
ments which, if present in the patient’s records, would render
the patient ineligible to the PROM, e.g. comorbidities in pa-
tients who would otherwise fit all other eligibility criteria.
(c) PROM evaluation model: contains the attributes measured
by the PROM, both mandatory and optional, their correspond-
ing questions which guide the patient as well as the range of
acceptable numerical values for each attribute. This model also
contains the method for computing PROMs based on the val-
ues of the attributes supplied by patients. This model maps to
polymorphic functions performing the actual calculation.
(d) Temporal model: contains temporal constraints associated
with the PROM including appropriate intervals between any PR-
OM instances for a patient, the number of PROM instances re-
quired (if applicable) as well as appropriate response intervals.
We define the various PROMs as instances in our ontology. The
mapping between PROMs and the eligibility model is many-
to-many as multiple PROMs can be found for a disorder, and
PROMs with similar eligibility models can match a single pa-
tient. We register organisation preferences with respect to the
PROMs used when multiple PROMsmap to a disorder or a drug.
Moreover, our agents are aware of their context-specific prefer-
ences and use them to assign PROMs to patients as Section 3.2
will show.
2. Naturalistic Treatment Trial Model: describes a single study
and is composed of the following submodels:
(a) Study description model: a free-text description of the
study’s purpose, length, funding body, participating organisa-
tions, target number of participants and authorised personnel.
(b) PROMs measured by the study: A single study can in-
volve one or more PROMs. The PROMs are described using the
model we have illustrated above.
(c) Study eligibility model: A naturalistic treatment trial study-
ing a certain PROM may have stricter eligibility requirements
than the PROM it measures. For instance, a scientist may be
interested in a specific age group or a specific stage of a disease.
Therefore, the study eligibility model uses an attribute set simi-
lar to the PROM attribute set to define constraints superimposed
on the corresponding PROM model associated with the study.
3.2 The System Design
As space constraints curtail the level of detail we are able to pro-
vide, we summarise our design in the modified agent class diagram
shown in Figure 1. The figure illustrates aspects of the system not
usually shown in agent class diagrams, including organisations of
the different agents, multiplicity constraints enforced on the agent
types, as well as the different actors, whom we refer to as stake-
holders. Solid lines indicate agent-agent interactions and dashed
lines indicate interactions involving at least one stakeholder. The
agent classes are also annotated with liveness policies of the agents
(the << policy >> slot) and roles played by each agent (the
<< plays >>> keyword), which are detailed in Tables 1 - 9. The
description of the goals as well as goal dependencies are described
in the text of the following sections. Similarly, we do not provide
figures showing the dynamics of agent interactions (e.g. protocol
diagrams) and resort to a textual description.
3.2.1 Overall Flow
There are two entry points to our system. The first is initiated
when a clinician enters the details of a new patient visiting a pri-
mary care clinic at a registered hospital. The DataManager agent,
having knowledge of all the PROMs and their corresponding pa-
tient specifications, informs the Clinician agent in real-time if the
patient details match an existing PROM. The clinician is then no-
tified through his agent and proceeds to explain the feedback pro-
cess to the patient, its benefits and procedure. The DataManager
agent maps the patient records to our uniform representation us-
ing the ontology for guidance, and sends the representation to the
UnitManager agent, which creates a PatientFollowUp agent for the
patient PROM pair. This agent locks to that patient, providing
timely communications containing guidance to self-care, detailed
progress-dependent reports and feedback requests on intervals de-
fined by the PROM’s specifications. The PatientFollowUp agent
also informs clinicians through their agents when patients are not
responsive and terminates upon clinician or patient requests.
Figure 1: Our Modified Agent Class Diagram
Alternatively, scientists located at a registered research facility
can initiate a naturalistic treatment trial study. When the specifica-
tions of the study are complete, the Scientist agent transfers them to
the UnitManager agent, which in turn makes them available to the
DataManager agent. In this scenario, clinicians are prompted in
real time if the patient is eligible for a running study. The clinician
is responsible for discussing the option of participation with the
patient, obtaining consent as well as explaining the difference be-
tween patient-reported feedback being a routine process carried out
to track the progress of the patient and issue interventions when re-
quired, and anonymous research studies requiring patient consent
(i.e. NTTs). If the patient consents to participating in the study,
the Clinician agent informs the DataManager agent, which anno-
tates the patient records sent to the UnitManager with the study de-
tails, and the feedback process proceeds as usual with the exception
that when the PatientFollowUp agent receives feedback, it updates
the UnitManager agent, which subsequently updates the study and
sends the anonymised data to the Scientist agent. If the patient has
not given consent, theDataManager agent only attaches the PROM
suitable for the patient when sending the records to the UnitMan-
ager agent and the Scientist agent remains uninvolved. We now
detail the design of the different agents.
3.2.2 DataManager Agent
As discussed earlier, a crucial issue in APPROaCh is protecting
the security of the patient records by prohibiting access by unau-
thorised personnel. However, as Figure 1 shows, patient records
are shared among several distributed agents and accessed by differ-
ent stakeholders. To ensure the secure transport of the data among
the system’s components, the DataManager agent, assuming the
DataProcessor role (Table 1), acts to map the patient records to
our internal representation and present views to the different agents
based on preassigned privileges.
Role Name DataProcessor
Description Maps newly-retrieved patient records to a uni-
form representation defined by our ontology &
creates an anonymised version of the records
Goals retrieveRecord, anonymiseRecord
Table 1: The Data Processor Role
Our DataManager agent is always running in the background,
monitoring the electronic patient records system of the hospital
where it resides in real-time for incoming records. An incoming
record activates the retrieveRecord goal, which maps the patient
attributes and relevant treatment details to our ontology, creating
an abstract representation understandable by all agents regardless
of their host institution and which will be used in lieu of the ac-
tual record. The retrieveRecord goal triggers the anonymiseRe-
cord goal, creating an anonymised version of the patient records
whereby all references to the patient’s identity (e.g. name, address,
PatientID) have been removed. The anonymised records are the
only versions of the records viewable less privileged agents, e.g.
the Scientist agent or agents locatd outside the unit. The reader
should note that the mapping between the retrieved records and our
abstract representation involves knowledge of the structures of the
patient records system of the hospital where the patient is receiv-
ing treatment and the extraction of terms from unstructured data (as
clinicians tend to use free text in describing the case). The details of
how the mapping is implemented is discussed in separate literature
(see [20]) and is beyond the scope of this work.
Our DataHander agent assumes two additional roles. The PRO-
MAllocationManager role (Table 2) awaits the completion of the
retrieveRecord goal, triggering the allocatePatient goal, which at-
tempts to map the patient to an appropriate PROM. The match-
ing is made possible by the fact that our DataManager receives all
the PROM and targeted studies specifications from the UnitMan-
ager agent (updateCriteriaList in Figure 1). If a match is found,
the patient PROM pair is passed to the UnitManager agent of the
unit where the agent resides (sendPatientRecord of Figure 1). We
achieve the matching between patients and PROMs using a simi-
larity measure briefly described below.
Let Ur be the set of attributes representing the specifications of
a given PROM, and let Up be a subset of the patient attributes such
that M : Up ! Ur is a one-to-one and onto mapping between
the attribute sets. The score given to the patient with respect to a
PROM A(Up,Ur) is given by:
A(Up,Ur) =
X
ui2Up
S(ui,M(ui))
Where S(ui,M(ui)) is the degree of similarity between ui and
the corresponding PROM attributeM(ui). For categorical attributes
(e.g. medication), S returns 1 if the value of the patient attribute ui
is an element of the set making up the permisible values of the cor-
responding PROM attribute, and 0 otherwise. Similarly for quan-
titative attributes (e.g. age), S returns 1 if the value of ui falls
within the allowed range of values of the corresponding PROM at-
tribute. The PROM allocated to a patient should maximise her A
score given the set of PROM specificationsR: -
A(Up,R) = argmax
Ur2R
A(Up,Ur) (1)
To ensure efficiency, we only compute A using the mandatory
attributes of available PROMs for every incoming patient record
(these usually include disease, medication and age group). When
a patient maps to several PROMs, the preventMultipleAssignments
goal is triggered, which uses the PROM’s optional attributes and
organisation-specific PROM preference ranking to find the match.
Role Name PROMAllocationManager
Description Defines the correspondence between PROMs
and diagnoses, drugs and other criteria
Goals allocatePatient, preventMultipleAssignments
Table 2: The PROM Allocation Manager Role
The DataManager agent also assumes the StudyAllocationMan-
ager role shown in Table 3, which oversees the allocation of patients
to naturalistic treatment trial studies they qualify for (detectEligi-
bility, which also maximises A for patient-study attribute sets).
This agent prompts the clinician with the patient’s eligibility in real
time (promptForRecruitment), who communicates the details to the
patient and consent (when provided by the Clinician agent) is com-
municated to the UnitManager agent along with the patient record.
This way, the UnitManager agent updates the corresponding study
when the patient completes a PROM.
Role Name StudyAllocationManager
Description Oversees the allocation of eligible patients
to studies defined by the Study Designer
Goals detectEligibility, promptForRecruitment, proc-
essRecruitment, preventMultipleAssignments
Table 3: The Study Allocation Manager Role
3.2.3 Scientist Agent
The Scientist agent is located at a research facility (e.g. univer-
sity), acting as a mediator between researchers and the rest of the
patient feedback system to assist scientists in formally designing
prospective naturalistic treatment trial studies. The StudyDesigner
role (Table 4) transforms scientists’ requests (received via fetchPre-
requisites in Figure 1) to a set of executable specifications (achiev-
ing the designStudy goal). When designStudy completes, it triggers
the agent’s checkStudy goal, which involves conversations with the
UnitManager agents of prospective healthcare units to ensure that
the units are capable of running the studies as Section 3.2.4 will
show. The Scientist agent has to wait until checkStudy returns the
responses of all registered UnitManager agents to make sure that
at least one unit accepts the study. If all units reject the study, then
checkStudy returns a failure notice to the scientist and the study
will not run in its current state. When checkStudy successfully
completes, the specifications are passed to the UnitManager agent
of units accepting the study through deliverSpecifications.
Role Name StudyDesigner
Description Responsible for defining the complete
specifications of a team-led study targeting
a specific patient cohort.
Goals designStudy, checkStudy,deliverSpecifications
Table 4: The Study Designer Role
This agent also assumes the CommunicationManager role (Ta-
ble 5), informing authorised scientists of the execution state of
the studies they are involved in by achieving patientCompletes,
studyCompletes and patientOptsOut. These goals are implemented
through eponymous polymorphic procedures, enabling them to use
different levels of anonymity depending on the privileges given to
the agent (only anonymised updates are seen by the Scientist agent).
Upon the scientist request, this agent is able to query the differ-
ent UnitManager agents about the progress of a study through the
queryStudyStatus procedure shown in Figure 1.
A single Scientist agent is assigned to every authorised scientist
machine and is created when the scientist designs her first study.
Although this agent’s main task is to transform study descriptions
into formal specifications understood by our agents, it also plays
a role in communicating study updates to the scientist. Therefore,
this agent remains alive as long studies it has helped designing are
still running and only terminates when no studies are ongoing. This
agent is created again when the scientist designs a new study.
Role Name CommunicationManager
Description Conveys timely progress messages to scientists
and clinicians throughout the trial
Goals patientCompletes, studyCompletes
patientOptsOut
Table 5: The Communication Manager Role
3.2.4 UnitManager Agent
A single UnitManager agent is located in every registered pri-
mary care unit and always runs in the background assuming two
roles. The PROMAgentAssigner role (Table 6) triggers the assign-
FollowUp goal when a patient  PROM or a patient study pair is
received from the DataManager agent, and creates a PatientFol-
lowUp agent for the patient, given the PROM or study.
Role Name PROM Agent Assigner
Description Oversees the creation of a PatientFollowUp
agent for an incoming patient
Goals assignFollowUp
Table 6: The PROM Agent Assigner Role
In addition, because this agent is the only bridge between the
Scientist agent and the rest of the system, it assumes the Gateway
role (Table 7), which involves performing all tasks requiring com-
munication with the Scientist agent. When UnitManager receives
a proposal for a new study from the Scientist agent, it triggers the
evaluateStudy goal to prevent implementing studies which are too
similar in the same care unit. This is essential because if two similar
studies are run in the same unit, the one with the more lenient eligi-
bility criteria tends to overshadow the other, rendering the second
study with few or no subjects. This agent uses our similarity func-
tion A to find the similarity between a proposed study and those
running in its unit and rejects the study if it achieves a similarity
above a certain threshold with one of its studies. EvaluateStudy
returns a decision to the Scientist agent, which is processed as Sec-
tion 3.2.3 discussed. This role also triggers the updateCriteriaList,
which passes the specifications of an approved study to the Data-
Manager agent of the unit to monitor incoming records as Section
3.2.2 discussed. Moreover, our UnitManager sends updates to the
scientists when studies they are involved in recruit new patients, a
new PROM is filled out or a patient drops (updateStudy).
Role Name Gateway
Description performs communication tasks between
the scientist agent and the rest of the system
Goals evaluateStudy,updateStudy, updateCriteriaList
Table 7: The Gateway Role
3.2.5 The PatientFollowUp Agent
The PatientFollowUp agent is created by the UnitManager agent
when a new patient maps to a PROM or a running study and locks to
the patient to guide the feedback process. This agent remains alive
for the duration of the study or until follow-up is terminated for the
patient. It follows a finite state machine (FSM) designed to satisfy
the goals of the FollowUpManager role (Table 8) and shown in Fig-
ure 2. The FSM starts when the the patient completes the registra-
tion as guided by the agent (guidePatientRegistration completes),
causing the agent to enter the Awaiting Outcome state in which no
PROM is due yet. The agent remains at this state as long as ti, a
timer which switches on when a PROM is due for the patient, is off
and as long as no new PROM is detected for the patient. As soon
as ti switches on, the agent enters the Outcome Due state and re-
mains there until a new PROM is recorded. When a new PROM is
found, the agent enters the Send Report state, where the agent sends
a report to the patient, along with informative figures evaluating the
patient’s progress based on the PROM. The agent then goes back to
the Awaiting Outcome (if no targeted studies have been assigned to
the patient or the number of PROMs required for the study assigned
to the patient have not been reached, both indicated by c = 0), oth-
erwise goes to DiscontinueFollowUp, which also implements the
informStudyComplete goal.
Role Name FollowUpManager
Description Tracks the progress of a single patient
Goals guidePatientRegistration, remindDue
sendReport ,discontinueFollowUp,
informUnresponsive, informpatientCompletes,
informStudyComplete, informPatientOptsOut
Table 8: The Patient Follow-up Manager Role
When in the Outcome Due state, the agent reacts to one signal,
R(tf ) = log10(tf ). tf starts as 1 and is incremented every time
the waiting period for reminding the patient elapses (e.g. every
Figure 2: The PatientFollowUp agent Finite State Machine
week). As one can see, the agent enters the Remind state right
after the first change in tf . When in this state, the agent sends a
reminder to the patient to fill out the new outcome measure. This
state has a natural transition (✏) back to the Outcome Due state.
When R(tf ) exceeds 0.4 (after four reminders ave been sent to the
patient), the agent enters the Inform state where the Clinician agent
is notified of the lack of participation from the patient (i.e. the
informUnresponsive). At this stage, the clinician can contact the
patient and decides whether the trial for this record should continue
or could manually kill the PatientFollowUp agent for this record.
When the SendReport state exits with c = 1, this indicates that
the record has completed the number of time points required for the
trial and the FSM goes to the final state and notifications are sent to
theUnitManager agent. All notifications sent toUnitManager trig-
ger its updateStudy goal, communicating the updates to respective
Scientist agents.
3.2.6 Clinician Agent
The Clinician agent acts on behalf of clinicians to automate the
aspects of the system requiring their involvement and to aid them
in achieving timely intervention when automation is not an option.
This agent assumes the RecruitmentManager role, which becomes
active when the DataManager agent detects patient eligibility for
a running naturalistic treatment trial study in real time, trigger-
ing promptForRecruitment to inform the clinician of the eligibil-
ity. When the clinician receives the alert via a pop-up message,
she is responsible for discussing the study with the patient and re-
questing consent. The clinician inputs the patient’s decision to the
system, and the Clinician agent communicates the decision to the
DataManager agent (through informRecruitmentDecision), which
updates the patient records sent to the UnitManager agent. This
agent also assumes the Communication Manager role, informing
the clinician when a patient becomes unresponsive (informInactive)
in order for the clinician to contact the patient.
4. PROTOTYPE AND STATUS QUO
In our work, we aimed to separate the design presented in Sec-
tion 3 from organisation-specific implementation details. This by
no means implies a large disparity between the envisioned system
Role Name RecruitmentManager
Description Oversees recruiting patients for studies
Goals requestRecruitment, confirmRecruitment
informRecruitmentDecision
Table 9: The Recruitment Manager Role
and the deployed infrastructure (with some exceptions as this sec-
tion will show), as our system was developed based on day-to-day
clinical requirements of UK-based healthcare trusts. However, we
set the separation so that the system can be applied to different
healthcare institutes and healthcare systems.
Here, we present our prototype, which targets a study whose re-
sults were the seeds of the collaboration resulting APPROaCh. The
study, mentioned in Section 1, examined 8,000 health records of
children diagnosed with ADHD and prescribed methylphenidate at
the South London and Maudsley National Health Services Foun-
dation Trust (SLaM). Methylphenidate is a highly-efficient drug.
Nevertheless, clinicians are ambivalent about the medication as it
is essentially a controlled drug (with a chemical structure similar
to cocaine). The aim of the study was to investigate the long-term
efficiency and side effects of methylphenidate. However, initial in-
vestigations found practically no long-term follow-up data for the
8000 patients investigated, with only 1% of the patients having
timely PROMs [5]. Subsequent inspections found that the lack of
outcome measures is not unique to the records investigated, drug
or disorder, and is especially common among patients who leave
the hospital to the community resulting no feedback. These are the
clinical concerns initiating the collaboration resulting APPROaCh.
Our prototype has been recently deployed across psychiatric clin-
ics as well as research facilities in SLaM to target the assessment
of ADHD progress. The PROM of interest in our study is the
well-established strength and difficulties questionnaire (SDQ) [8]
for evaluating children and adolescents’ mental health and filled by
the patients or their guardians. The SDQ comprises of 25 ques-
tions measuring 25 attributes of the child’s emotional, conduct and
peer relationship health and whose values are added according to
the SDQ formula [8] to provide the total difficulties score.
4.1 Prototype Implementation
We implemented APPROaCh using JADE (Java Agent DEvelop-
ment Framework). The system communicates with patients through
IntelliFollow, a Microsoft Healthvault web application2 realised via
myhealthlocker3: a King’s-trusted application ensuring the secure
transport data between the Healthvault web platform and the hospi-
tals’ internal electronic health records systems. Patients are advised
to register with Microsoft HealthVault and are directed by email
to IntelliFollow, where secure login instructions are provided. We
used the JadeGateway API4 to bridge the APPROaCh agents with
the web-based IntelliFollow. Currently, a large portion of the over-
all design has been implemented, with some agents not requiring
their full capabilities as will be clear shortly. We used Protégé to
create our cross-platform ontology. The ontology’s PROM object
currently has a single instance: SDQ, as our prototype targets this
specific PROM. We used JadeJessProtege5 to transform our ontol-
ogy into a JADE ontology understandable by all agents. The next
section discusses agent-specific deployment.
2https://developer.healthvault.com/
3https://www.myhealthlockerlondon.nhs.uk/PrivacyPolicy.aspx
4http://jade.tilab.com/doc/api/jade/wrapper/gateway/JadeGateway.html
5http://sourceforge.net/projects/jadejessprotege/
4.2 Deployment
1. DataManager agent: So far, this agent has been deployed within
the Electronic Patient Journey System (ePJS), the electronic health
records system used in most of King’s health partners hospitals.
Four DataManager agents have been placed in four psychiatric
clinics located in different sites. Currently,DataManager recog-
nises the SDQ eligibility criteria and monitors ePJS for incom-
ing records which match it.
Although this agent’s multiple PROM prevention capabilities
have been implemented, DataManager does not currently make
use of them as we have only deployed the SDQ PROM. As soon
as the Clinician agent is informed of a qualifying record, it uses
the anonymisation pipeline described in [4] to create a research-
friendly version of the patient records whereby all references to
the patient’s identity are removed. The anonymised records are
stored in the Clinical Record Interactive Search (CRIS) database
[20], a research database containing over 250,000 detailed and
anonymised records of mental health patients. CRIS is a trusted
research repository established in 2008 through the National In-
stitute of Health Research Biomedical Research Centre (NIHR
BRC) at SLaM with access requiring a Disclosure and Barring
Service (DBS) check. Only CRIS records are used to update
the Scientist agent and agents residing in other hospitals with no
authorisation to the hospital health records.
2. Scientist agent: We implemented our Scientist agent within a
graphical toolkit designed to allow the design and submission
of studies by authorised scientists. So far, we deployed a single
instance of our agent in the Biomedical Research Council Nu-
cleus at King’s College London6, a research insititution founded
to facilitate research activities between SLaM and King’s Col-
lege London. The Scientist agent can only design trials involv-
ing authorised variations of the SDQ PROM. We impelemented
checkStudy using contract Net with the Scientist agent being the
initiator and the four UnitManager agents being the responders.
3. UnitManager agent Four UnitManager agents live in our par-
ticipating clinics, with one in each clinic. These agents are trig-
gered by messages received from the four DataManager agents
of their respective clinics as well as our single Scientist agent.
4. PatientFollowUp agent: This agent is created on a per-patient
basis. Projections from examining CRIS records showed that
on average, 900 ADHD patients are seen annually, reflecting
the anticipated number of agents created of this type. Patient-
FollowUp agents communicate with patients via regular e-mails
with different purposes ranging from induction, login and ac-
count creation, provision of online resources suitable for the
case, graphical views of personal progress as well as timely re-
minders for entering new SDQ values. Patients are directed to
the IntelliFollow web tool, where they can view their progress
and enter new SDQ values.
5. Clinician agent: We installed Clinician agents on 19 machines
located across the four clinics. The agent communicates with
clinicians by providing a pop-up if the patient is eligible for a
study. Since study selection for the patient is handled by the
DataManager agent, a single pop-up is guaranteed to appear on
the clinician’s machine (not applicable to our single-PROM pro-
totype). The pop-up message has a box which can be ticked by
the clinician if the patient consents to the study, and no further
6http://www.slam.nhs.uk/about/core-facilities/brc-nucleus
interaction is required unless the patient becomes unresponsive.
When this happens, a pop-up appears on the clinician’s screen
to which the clinician can respond to by contacting the patient.
The clinician can also mute the pop-up for a user-specified in-
terval or indefinitely, the latter not being recommended.
4.3 Evaluation
In this work, our evaluation focuses on insuring that the differ-
ent aspects of our system work as envisioned. Due to space con-
straints, we present two experiments, one evaluating the efficiency
in recognising eligible patient records and another testing our sim-
ilarity measure. We used a test (non-live) version of ePJS.
1. Response Time: In order to test the efficiency of patient-PROM
and patient-study matching in real-time, we studied the relation-
ship between the complexity of the PROM eligibility criteria
and the time taken to complete the matching process. We ex-
perimented by varying the SDQ eligibility criteria to create 16
cases representing SDQ criteria containing 4-19 attributes. For
each case, we tested our agents by populating our non-live ePJS
with 20 patient records in real time and recorded the time our
ClinicianAgent reacted with a pop-up message. Our test results
show that the maximum response time was 8.38 seconds (oc-
curred in a test set with 19 attributes), which was assessed by
the clinicians in our team to be adequate with respect to consul-
tation time. The average response time ranged from 1.2 seconds
(for test sets having 4 attributes) to 7.79 seconds (for test sets
with the maximum number of attributes).
2. Study Allocation: We tested the UnitManager’s effectiveness
in rejecting proposed studies which are two similar to ones it is
currently running. We initiated 20 fictitious NTT studies, using
variations of the SDQ and whose eligibility models vary across
age group, medications and gender. We designed the studies so
that they comprise of pairs, with each study pair being made of
two studies overlapping in one of the following two ways:
(a) proper-subset similarity: studies whose mandatory attribute
values are either subsets of supersets of other studies, e.g. a
study with age group 5-7 and another with age group 4-14.
In this case, our four UnitManager agents successfully re-
ject proposed studies whose mandatory attribute values are
subsets or supersets of studies running in their units.
(b) intersection overlap: studies sharing similar attributes but
also contain conflicting sets of attributes. Our UnitMan-
ager agents successfully reject studies whose mandatory
attributes achieve similarity of 20% or greater with stud-
ies they are currently running. The rejection threshold was
chosen based on discussions with clinical workers at SLaM.
5. CONCLUSIONS, CHALLENGESANDFU-
TUREWORK
We presented the design and prototype deployment of a system
countering a real clinical need. The lack of measurable treatment
outcome measures in clinical settings has been shown to hinder
long-term investigations and patient care, scientific inquiry as well
as objective quality control and auditing inquests. The initial anal-
ysis uncovered real issues which we summarise as: 1) security
issues, springing from the confidential nature of patient records,
making any system involving their manipulation and transport chal-
lenging to realise. This is complicated further when stakeholders
not directly involved in the treatment have real interest in the data
(scientists), and when patients are granted the right to add to their
clinical records from outside the hospitals where they are seeking
treatment 2) distribution issues, embodied by the fact that a single
patient can visit one or more hospitals for treatment, making his
records distributed across different units or organisations 3) data
diversity issues, arising from the diversity of medical terminology
and electronic health records systems used in the different organ-
isations. These challenges made it obvious that the key to a suc-
cessful design is the avoidance of a traditional healthcare system.
We therefore designed and implemented APPROaCh, a multi-agent
system targeting the above issues. We handled the security issue by
implementing a pipeline which anonymises the patient records and
granting varying privileges to the different agent types depending
on their role, with only agents representing personnel involved in
the patient’s treatment being allowed to access the actual identifi-
able patient data. Other agents (e.g. Scientist agents) can only view
the anonymised records. We dealt with the distribution and data
diversity issues by equipping our system with an ontology unifying
the organisational variations of data and systems to create a repre-
sentation understood by all agents involved, regardless of their host
institution. This representation also allows patients to interact with
our web tool regardless of the hospital(s) where they are seeking
treatment. Our webtool is built to understand our unified represen-
tation, which is then used to map the data entered by patients to the
electronic health records systems of the respective hospitals.
We implemented a prototype targeting ADHD patients and have
recently deployed it across mental health clinics in SLaM, London,
U.K.; it has so far been well-received. The work presented in this
paper aims at examining the technical hurdles we faced in imple-
menting such system in a domain where privacy, security, data di-
versity and guidelines adherence are major bottlenecks. However,
the long-term effectiveness of the automated system can only be
established once long-term data is available.
In addition to validation through data collection, there are sev-
eral issues which our current deployment does not validate. Since
our prototype targets a single PROM, the DataManager’s multiple-
PROM prevention functionality is not used. The same applies to
situations where conflicts arising from organisational preferences
with respect to PROMs require resolution for consolidation into
prospective studies. The incorporation of future PROMs in our
system is an ongoing long-term process and requires authorisations
from clinical, technical and governance bodies. The approval pro-
cess is partially dependent on the success of the current prototype
in increasing patient involvement in outcome measure collection as
well as anonymised clinical trials.
Our experience in working with healthcare systems has come
with many legal and security challenges. In deploying our proto-
type, we worked in an environment where the following is avail-
able: 1) the CRIS research database, with strict access provided
to authorised scientists. This resource has eased the automation of
the anonymisation pipeline of the health records and provided an
existing trusted reserve for new data 2) an already-approved Mi-
crosoft Healthvault web-based API for reading from and writing to
the electronic health records systems of the units where our system
is deployed. Obtaining the required authorisation and completing
the legalities to use these two resources have been not only time-
consuming, but also a deciding factor in implementing our proto-
type. Moreover, since these resources are limited to King’s Col-
lege Health Partners, any expansion to further organisations will
involve tackling the bureaucracies and legal and organisational re-
strictions associated with setting up similar resources (or finding
alternatives).
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